NEUNEUREN PHARMACEUTICALS LIMITED

NNZ-2591 PMS Phase 2 trial published in Neurology Genetics

Date and time
Announcement type
Company Update

More from Health Care

More News

ARLCompany Update12 November 2026

Ardea Resources (ASX: ARL) Scandium Study Models US$510m NPV